Cimifugin

• UNSPSC Description:

  Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions[1]. Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS[2].

• Target Antigen:

  NF-κB

• Type:

  Natural Products

• Related Pathways:

  NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Cimifugin.html

• Purity:

  99.95

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C(CO)OC2=CC(O[C@H](C(C)(O)C)C3)=C3C(OC)=C12

• Molecular Weight:

  306.31

• References & Citations:

  [1]Xiaoyu Wang, et al. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions. J Cell Mol Med. 2017 Nov;21(11):2926-2936.|[2]Han B, Dai Y, Wu H, et al. Cimifugin Inhibits Inflammatory Responses of RAW264.7 Cells Induced by Lipopolysaccharide. Med Sci Monit. 2019;25:409-417.|[3]Duan J, Hu X, Li T, Wu G, Dou P, Ouyang Z. Cimifugin Suppresses NF-κB Signaling to Prevent Osteoclastogenesis and Periprosthetic Osteolysis. Front Pharmacol. 2021;12:724256.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  37921-38-3